Author's response to reviews

Title: Anti-tumor effect of Liqi, a Traditional Chinese Medicine prescription, in tumor bearing mice

Authors:

Ji Deng-Bo (jidengbo.peking@yahoo.com.cn)
Ye Jia (yejia@bjmu.edu.cn)
Qian Bo-Wen (qianbowen@gmail.com)
Jiang Yi-Min (jiangyimin@bjmu.edu.cn)

Version: 2 Date: 19 August 2008

Author's response to reviews: see over
Dear Editor,

We would like to submit the enclosed manuscript entitled “Anti-tumor effect of Liqi, a Traditional Chinese Medicine prescription, in tumor bearing mice”, which we wish to be considered for publication in BMC Cancer.

We state that our manuscript has not and will not be submitted for publication elsewhere. We declare that the laboratory animal protocol used for this study was approved by committee for the purpose of control and supervision on experimental animals, ShangHai University of Chinese Traditional Medicine, China.

"Liqi prescription ", a Traditional Chinese Medicine prescription has been used as antitumor herb in Chinese traditional medicine. We investigated for the first time the anti-tumor effect of “Liqi” prescription and its mechanism on tumor bearing mice. Our results showed that Liqi inhibited the tumor growth in tumor implanted mice, and arrested the cell proliferation in the G0/G1 phase and reduced the portion of cells in S and G2/M phase for SGC-7901 cells. Liqi increased the activity of NK cells and TNF-α, stimulated IL-2 production and activity, and regulated T lymphocyte subpopulations significantly. Liqi inhibited the Lewis lung carcinoma metastasis through inhibiting platelet aggregation and normalizing the balance between TXA2 and PGI2. All these findings demonstrated that Liqi has an anti-tumor effect in vivo and the mechanism may be related to its immune regulation and anticoagulation.

All authors have seen the manuscript and approved to submit to your journal.

Thank you very much for your attention and consideration.

Sincerely yours,

YeJia